These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 20446892)

  • 21. A phase II trial of paclitaxel poliglumex in recurrent or persistent ovarian or primary peritoneal cancer (EOC): a Gynecologic Oncology Group Study.
    Sabbatini P; Sill MW; O'Malley D; Adler L; Secord AA;
    Gynecol Oncol; 2008 Dec; 111(3):455-60. PubMed ID: 18829087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
    Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective evaluations of continuous weekly paclitaxel regimen in recurrent platinum-resistant epithelial ovarian cancer.
    Le T; Hopkins L; Baines KA; Rambout L; Al Hayki M; Kee Fung MF
    Gynecol Oncol; 2006 Jul; 102(1):49-53. PubMed ID: 16375951
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paclitaxel-induced myocardial infarction in a case of carcinoma ovary.
    Londhey VA; Parikh FS
    J Assoc Physicians India; 2009 Apr; 57():342-3. PubMed ID: 19702043
    [No Abstract]   [Full Text] [Related]  

  • 25. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
    Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [A case of gastric cancer with peritoneal dissemination which shows a remarkable efficacy by a weekly administration of paclitaxel intraperitoneally].
    Kato K; Koide A; Oobu M; Hasegawa K; Maruyama S; Takashima I; Nagahama T; Maruyama M; Ebuchi M
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1852-4. PubMed ID: 15553737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study.
    Armstrong DK; Fleming GF; Markman M; Bailey HH
    Gynecol Oncol; 2006 Nov; 103(2):391-6. PubMed ID: 16626792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Taxol in the treatment of ovarian neoplasm].
    Wang Y; Huang R; Huang H
    Zhonghua Fu Chan Ke Za Zhi; 1999 Jul; 34(7):439-41. PubMed ID: 11360659
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy.
    Zanotti KM; Belinson JL; Kennedy AW; Webster KD; Markman M
    Gynecol Oncol; 2000 Nov; 79(2):211-5. PubMed ID: 11063646
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Salvage weekly paclitaxel in recurrent ovarian cancer.
    Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Feasibility, activity, and change in the level of blood paclitaxel concentration after weekly paclitaxel therapy for a patient with recurrent ovarian cancer].
    Ishioka S; Sagae S; Kudo R
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):1017-21. PubMed ID: 11478132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Paclitaxel].
    Díaz M; Campanero MA
    Rev Med Univ Navarra; 1996; 40(3):43-51. PubMed ID: 9499826
    [No Abstract]   [Full Text] [Related]  

  • 34. Scleroderma and the taxanes. Is there really a link?
    Farrant PB; Mortimer PS; Gore M
    Clin Exp Dermatol; 2004 Jul; 29(4):360-2. PubMed ID: 15245529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extravasation of paclitaxel into breast tissue from central catheter port.
    Barutca S; Kadikoylu G; Bolaman Z; Meydan N; Yavasoglu I
    Support Care Cancer; 2002 Oct; 10(7):563-5. PubMed ID: 12324812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.
    Meerpohl HG; du Bois A; Kühnle H; Lück HJ; Kreienberg R; Möbus V; Bauknecht T; Köchli O; Bochtler H; Diergarten K
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):7-12. PubMed ID: 8643973
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emergency. Chemotherapy-induced hypersensitivity reaction.
    Myers JS; Kearney K
    Am J Nurs; 2000 Apr; 100(4):53-4. PubMed ID: 10776352
    [No Abstract]   [Full Text] [Related]  

  • 39. Scleroderma-like cutaneous lesions induced by paclitaxel: a case study.
    Kupfer I; Balguerie X; Courville P; Chinet P; Joly P
    J Am Acad Dermatol; 2003 Feb; 48(2):279-81. PubMed ID: 12582404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A phase I study of intraperitoneal plus intravenous paclitaxel against gastric cancer with peritoneal dissemination (HGCG 0301)].
    Shinohara H; Okamoto S; Nishitai R; Shirakata Y; Itoi K; Yamagami K; Taki Y; Yamamoto M; Mizuno Y
    Gan To Kagaku Ryoho; 2006 Dec; 33(13):2027-31. PubMed ID: 17197747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.